Top Polish (WIG) Growth Stocks

Top Polish (WIG) Growth Stocks

UPDATED Jun 29, 2022

What are the best Polish (WIG) Growth Stocks?

According to our Simply Wall St analysis these are the best Polish growth companies. We look for companies with high forecasted growth and healthy balance sheets that can deliver sustained growth over the long term.

Our criteria to find Top Growth Companies

Growth

  • Companies with sustained revenue growth that outperforms the market are attractive to investors. These companies are most likely to appreciate in share price over time.

What do we look for?

  • Is the company forecast to have high earnings growth.

Healthy Balance Sheet

  • A healthy balance sheet is essential to drive growth opportunities and sustain the business.
  • Repayments on debt take precedence over other initiatives to improve shareholder returns, so investors want to make sure the company is comfortably positioned to cover its debts.

What do we look for?

  • Does the company have a manageable level of debt.
  • Is the company able to cover its interest repayments.

5 companies meet this criteria in the Polish market

MedApp S.A. develops mobile solutions for medicine in Poland.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: MDA's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 75.5% below our estimate of its fair value

  • Earnings are forecast to grow 43.64% per year

  • Earnings grew by 57.3% over the past year

Risks

  • High level of non-cash earnings

  • Does not have a meaningful market cap (PLN143M)

  • Does not have meaningful revenue (PLN14M)

  • Volatile share price over the past 3 months

View all Risks and Rewards

Creepy Jar S.A. develops survival simulator games in Warsaw.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: CRJ's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 58.3% below our estimate of its fair value

  • Earnings are forecast to grow 29.54% per year

  • Earnings grew by 79.6% over the past year

Risks

  • High level of non-cash earnings

  • Does not have a meaningful market cap (PLN331M)

View all Risks and Rewards

LPP SA designs, manufactures, distributes, and retails clothing for women, men, and children.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: LPP's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • Future ROE

  • High Growth Revenue

See Full Stock Report

Rewards

  • Trading at 24.8% below our estimate of its fair value

  • Earnings are forecast to grow 25.85% per year

  • Earnings grew by 520.4% over the past year

Risks

  • Large one-off items impacting financial results

View all Risks and Rewards

11 bit studios S.A. develops and sells cross-platform video games worldwide.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: 11B's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 21.7% below our estimate of its fair value

  • Earnings are forecast to grow 114.54% per year

  • Earnings have grown 19.9% per year over the past 5 years

Risks

No risks detected for 11B from our risks checks.

View all Risks and Rewards

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: MAB's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • Future ROE

  • High Growth Revenue

See Full Stock Report

Rewards

  • Price-To-Earnings ratio (13.3x) is below the Biotechs industry average (25.1x)

  • Earnings are forecast to grow 70.57% per year

  • Became profitable this year

Risks

  • High level of non-cash earnings

  • Does not have a meaningful market cap (PLN359M)

  • Volatile share price over the past 3 months

View all Risks and Rewards
Page 1 of 1